1-substituted-7-(β-D-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same
申请人:Kissei Pharmaceutical Co., Ltd.
公开号:US07749972B2
公开(公告)日:2010-07-06
The present invention provides a compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity or the like.
It is a 1-substituted-7-(β-D-glycopyranosyloxy)(aza)-indole compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:
wherein R1 represents a halogen atom or the like; n represents j an integer number from 0 to 3; R2 represents a hydrogen atom or the like; X represents a carbon atom which a hydrogen atom or the like binds to, or a nitrogen atom; Q represents an alkylene group or an alkenylene group each of which may have an oxygen atom or a sulfur atom in the chain; and A represents an aryl or heteroaryl group which may have a substituent.
本发明提供了一种具有SGLT1和/或SGLT2抑制活性的化合物,可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖症等药物。它是一种代表通式(I)的1-取代-7-(β-D-葡萄糖苷基氧)(氮)吲哚化合物,其前药,或其药学上可接受的盐,或其水合物或溶剂化物:其中R1代表卤素原子或类似物;n代表0至3的整数;R2代表氢原子或类似物;X代表与碳原子结合的氢原子或类似物,或氮原子;Q代表可以在链中具有氧原子或硫原子的烷基或烯基基团;A代表可以具有取代基的芳基或杂环基团。